The rapidly evolving landscape of biomarker testing in non–small cell lung cancer
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncy.22334
Reference18 articles.
1. Surveillance Epidemiology and End Results Program.Cancer Stat Facts: Lung and Bronchus Cancer. Statistics at a Glance. Accessed July 1 2020.http://seer.cancer.gov/statfacts/html/lungb.html
2. US Food and Drug Administration.Hematology/Oncology (Cancer) Approvals & Safety Notifications. Accessed July 1 2020.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/hematologyoncology‐cancer‐approvals‐safety‐notifications
3. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
4. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
5. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update;Kalemkerian GP;J Clin Oncol,2018
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Next-Generation Sequencing in Lung Cancers—A Single-Center Experience in Taiwan;Medicina;2024-01-29
2. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates;Translational Lung Cancer Research;2023-07
3. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors;Lung Cancer;2023-07
4. Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer;Journal of Personalized Medicine;2023-01-17
5. Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing;Journal of the American Society of Cytopathology;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3